Scientific Posters

Fibrosis regression after Tirzepatide treatment of Non- cirrhotic MASH for 52 weeks occurred in a zone-dependent manner

November 28, 2024

Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis

November 28, 2024

Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study

November 28, 2024

AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study

November 28, 2024

Evaluating impact of weight changes on histological patterns of liver fibrosis in MASH: implications for spatial interrogation

November 28, 2024

Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH

November 28, 2024

Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease

November 28, 2024

Evaluation of the consistency and heterogeneity of fibrosis assessment in adjacent virtual liver needle biopsies using AI- based qFibrosis

November 28, 2024

Independent validation of Second Harmonic Generation/Two- photon excitation imaging and artificial intelligence-based SNOF index for metabolic dysfunction associated steatohepatitis cirrhosis assessment

November 28, 2024

Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease

November 28, 2024

Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease

June 7, 2024

Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH

June 7, 2024

GWAS analysis and digital pathology at patients without MASLD improvements prospective cohort 1 year study

June 7, 2024

qBallooning AI-based ballooned hepatocyte detection and quantification by SHG TPE microscopy

June 7, 2024

Regional fibrosis progression analysed by digital pathology with artificial intelligence is associated with renal dysfunction

June 7, 2024

AI Digital pathology unmasked the “No Change” in conventional pathological assessment of MASLD patients with one year lifestyle intervention in a prospective cohort study

June 7, 2024

Validation of optimal liver biopsy size for reliable quantitation of fibrosis severity in different areas and structure of liver lobule using SHG with AI analyses

June 7, 2024

Assessment of fibrosis changes rates in placebo arm of MASH drug trials based on pathologist readouts and qFibrosis continuous values

June 5, 2024

Impact of sampling size on variability of fibrosis assessment in liver biopsies using SHG TPE and AI analysis based fibrosis staging

November 12, 2023

NITs as continuous measure of hepatic fibrosis in NAFLD

November 11, 2023

Validation of the HI AI DP platform as an aiding tool to increase pathologist concordance on fibrosis staging in NASH

November 11, 2023

Reducing screen failure rates for NASH clinical trials using ballooning and fibrosis assessment with SHG TPE microscopy and AI analysis – results from the TANDEM trial

November 11, 2023

Spatial distribution of collagen in MASLD affects levels of N terminal pro-peptide of type III collagen (PRO-C3)

November 11, 2023

The concomitant zonal quantification of qSteatosis and qFibrosis using HI AI DP improved detection of liver injury regression post-bariatric surgery

November 11, 2023

Differential anti-fibrotic effects of semaglutide and lanifranor demonstrated by AI DP in the biopsy-confirmed GAN BIO-MASH mouse model with advanced fibrosis and HCC

November 11, 2023

Assessment of resmetiron-mediated reductions of steatosis and concomitant ballooning utilizing quantitative SHG imaging

November 11, 2023

Use of multi-parametric measures to differentiate and better assess fibrosis patterns between baselie and EOT patients in NASH clinical trials – Results from the FALCON-1 and 2 clinical trials

November 11, 2023

Digital quantitation of fibrosis, septa parameters and treatment-induced changes in metabolic dysfunction-associated steatohepatitis F3 fibrosis

September 7, 2023

Comparing fibrosis distribution in lean versus overweight/obese NASH-cirrhosis patients using SHG/TPE microscopy: An observational analysis

September 7, 2023

Artificial Intelligence to Measure Fibrosis Change on Liver Biopsy in MAESTRO-NASH, a Phase 3 52-Week Serial Liver Biopsy Study in 966 Patients With NASH Treated With Resmetirom or Placebo

September 7, 2023

Impact of sampling size on variability of fibrosis assessment in liver needle biopsies using second harmonic generation/two photon excitation microscopy and artificial intelligence analysis based fibrosis staging

September 7, 2023

Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves nonalcoholic steatohepatitis (NASH) in a GAN diet induced and biopsyconfirmed mouse model

June 21, 2023

Validation and utility of artificial intelligence-based zonal annotations as an additional assessment tool for the histopathologic review of fibrosis in non alcoholic steatohepatitis patients

June 21, 2023

Artificial intelligence assisted qFibrosis as a pathological “biomarker” to evaluate disease severity in patients with hepatocellular carcinoma

June 21, 2023

Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH a phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo

June 21, 2023

A deep exploration of bridging fibrosis evolution and individual septa parameters in NASH using quantitative second harmonic generation imaging reveals fibrosis changes in natural history and treatment-induced not seen with conventional histology

June 21, 2023

Quantification of vessel and bile duct parameters using Second Harmonic Generation in patients with NAFLD across fibrosis stages

June 21, 2023

Digital pathology using stain-free imaging indices as a tool for fibrosis quantification in patients with congestive hepatopathy

June 21, 2023

Artificial Intelligence analysis of liver biopsies in pre-cirrhotic NASH: qFibrosis explained

June 21, 2023

Repeatability and reproducibility assessment and its acceptable standard error of means for qFibrosis system in multi site NASH clinical trials

June 21, 2023

Digital pathology with artificial intelligence analyses provides deeper insights into lifestyle intervention-induced fibrosis regression in NASH

June 21, 2023

Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models

June 21, 2023

Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty liver disease

June 21, 2023

Hepatic fat and liver volume reductions-impact on non-alcoholic steatohepatitis trials and potential solutions using concomitant fibrosis with ballooning with fibrosis

June 21, 2023

Advancement of artificial intelligence in digital pathology: from exploratory end point to primary end point in non-alcoholic steatohepatitis clinical trials

June 21, 2023

Understanding early stage fibrosis in NASH non-human primate model using AI digital pathology

June 1, 2023

Histological Correlation with Portal Pressures and Varices in NASH Cirrhosis using Quantitative Digital Pathology

November 4, 2022

Quantitative Assessment of Septa Formation and Progression in CDHFD Rat Model of NASH Using SHG/TPEF Microscopy

November 4, 2022

Quantitative Assessment of Septa Formation and Progression in CDHFD Rat Model of NASH Using SHG/TPEF Microscopy

November 4, 2022

Repeatability and reproducibility of qFibrosis for automated assessment of liver fibrosis

November 4, 2022

Use of Second-Harmonic Generation Microscopy for Automated Detection of Septa and Nodules in Needle Liver Biopsies of NASH Cirrhosis

June 22, 2022

Clinical relevance of an animal model of nonalcoholic steatohepatitis (NASH) and digital pathology with artificial intelligence (DP-AI) analyses of hepatic fibrosis

June 22, 2022

Derivation of Machine Learning Histologic Scores Correlating with Portal Pressures and the Development of Varices in NASH Patients with Cirrhosis

June 22, 2022

Impact of Artificial Intelligence Assistive Tool on the Histopathologic Review of Fibrosis in Non-Alcoholic Steatohepatitis Patients

June 22, 2022

Magnetic Resonance Elastography (MRE) Demonstrate the Strongest Correlation with Digital Pathology and NASH CRN Fibrosis Assessments, compared to Transient Elastography and Other Assessed Non-Invasive Tests (NITs)

June 22, 2022

Second Harmonic Generation Microscopy can Quantify and Subclassify Early Stages of NASH Fibrosis Progression: Data from a screen-failure cohort of a NASH phase 2 study

June 22, 2022

Characterisation of the novel Galectin-3 inhibitor GB1107 on CCl4-induced liver fibrosis in mice

June 22, 2022

Impact of Resmetirom-Mediated Reductions in Liver Volume and Steatosis Compared with Placebo on the Quantification of Fibrosis using Second Harmonic Generation in a Serial Liver Biopsy Study

June 22, 2022

Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment

June 22, 2022

Addressing the Heterogeneity of Fibrosis in Liver Biopsy Specimens with qFibrosis – a New Paradigm for an Old Problem

June 22, 2022

The Complexity of Ballooned Hepatocyte (BH) Identification: Time to Rethink Trial Endpoints for Nonalcoholic Steatohepatitis?

November 12, 2021

Development of Machine Learning Histological Scores that Correlated with Portal Pressures and Development of Varices in NASH patients with Cirrhosis

November 12, 2021

Unique fibrosis progression and regression features in NAFLD, validation of concept in animal and human studies using artificial intelligence analyses (DP-AI)

November 12, 2021

SHG/TPEF Microscopy Imaging in the Fibrosis and Steatosis Progression of Nonalcoholic Fatty Liver Disease (NAFLD) in Mouse Models

November 12, 2021

Second Harmonic Generation (SHG)/Two-Photon Excitation Fluorescence (TPEF) Microscopy Imaging and Quantitative Assessment of Septa Fibrosis in Choline Deficient High Fat Diet (CDHFD) Rat Model of Nonalcoholic Steatohepatitis (NASH)

November 12, 2021

qVessel, a Machine Learning-based Algorithm, Accurately Stages Liver Biopsies with Chronic Liver Disease, based on Automated Vessel Counting

November 12, 2021

AI Digital Pathology Using qFibrosis Reveals Heterogeneity of Fibrosis Regression in Hepatitis B and Hepatitis C Patients with SVR

June 23, 2021

Digital Pathology with Artificial Intelligence Analyses Reveal New Dynamics of Treatment Induced Fibrosis Regression in Nonalcoholic Steatohepatitis

June 23, 2021

Dynamic Fibrosis Features in HCV Post-treatment Liver Biopsies and Its Interpretation

February 3, 2021

Predict Early Recurrence of Hepatocellular Carcinoma Using Multi-dimensional Artificial Intelligence Analysis of Liver Fibrosis

February 3, 2021

The Significance Of Quantified Extracellular Matrix Features In Patients With Hepatocellular Carcinoma After Curative Liver Resection

February 2, 2021

Dynamic Fibrosis Features in Post-treatment Biopsies and its Interpretation

October 22, 2020

BMS-986263 (Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA) Safety and Target Engagement in Patients with Advanced Hepatic Fibrosis: Week 36 Results from a Phase 2 Randomized, Double-blind, Placebo-controlled Trial

August 27, 2020

Concomitant Zonal Quantification of qSteatosis and qFibrosis in a Sub-study from EMMINENCE, a 12-month Phase 2b NASH study of MSDC-0602K

January 9, 2020

Steatosis and Fibrosis Measured as Continuous Variables on Paired, Serial Liver Biopsies in the Resmetirom (MGL-3196) 36-week Phase 2 NASH Study

November 8, 2019

qFIBS for the Automated Quantitative Evaluation of Histological Evolution in Pediatric Nonalcoholic Steatohepatitis

November 8, 2019

Quantitative Imaging and Characterization of Collagen Patterns in High Grade Serous Ovarian Carcinoma (HGSOC)

September 27, 2019

Comparison of Various Quantitative and Qualitative Collagen Analysis Methods in Early Liver Fibrosis

June 16, 2019

The Glucocorticoid Antagonist ST001 Prevents Development of NASH and Improves Aspects of the Metabolic Syndrome in the DIAMOND™ Mouse Model

April 10, 2019

Morphometric Collagen Analysis Discerns Anti-fibrotic Effects of INT-767 and OCA in NASH Mouse Models Using Second Harmonic Generation Imaging

April 10, 2019

Long-Term Obeticholic Acid Treatment is Associated With Improvements in Collagen Morphometry in Patients With Primary Biliary Cholangitis

April 10, 2019

Multi-photon Microscopy for Characterization of Renal Cell Carcinoma Pseudocapsule: Implications for Tumour Enucleation

March 15, 2019

To Improve the Current Quantitative Assay of Liver Fibrosis by Second Harmonic Generation Microscopy

November 8, 2018

New Automated Evaluation Tool qFIBS – Quantitative Assessment for Fibrosis, Inflammation, Ballooning, and Steatosis in Patients with Non-Alcoholic Steatohepatitis

November 8, 2018

A Better Quantitative Method to Evaluate Liver Fibrosis of Short Liver Biopsy Samples in Chronic Hepatitis B Patients

November 8, 2018

Assessment of Collagen in Human Idiopathic Pulmonary Fibrosis Using Second Harmonics on Genesis®200

September 15, 2018

Effect of a Small Natural Dietary Compound on Lung Pathology in Airway Inflammation

September 15, 2018

Quantitative Imaging and Deep Profiling of Collagen Structure in Triple Negative Breast Cancer

March 17, 2018

Development and Validation of an Automated Assessment of Liver Fibrosis Using SHG in Patients with NAFLD

April 19, 2017

Automated, fully quantitative analysis by using second harmonic generation microscopy in the fibrosis progression of nonalcoholic fatty liver disease

April 19, 2017

Quantification of Septa in Liver Fibrosis Using Second Harmonic Generation Imaging

March 26, 2017

Concurrent Semi-Automated Quantification of Liver Fibrosis and Fat Using Label-free Second Harmonic Generation Imaging in Animal Models

March 26, 2017

Phenotypical Characterization of Intrahepatic Cholangiocarcinomas Stroma: The More Fibrous, the Less Pejorative

November 11, 2016

Quantitative Assessment for Fibrosis in NAFLD Using Collagen String Features in Specific Regions for Liver

February 20, 2016

Digital Whole Slide Imaging and Two Photon Microscopy for Liver Fibrosis Scoring and Quantification

March 21, 2015

Stain-free Detection of Bone Marrow Fibrosis Using Two Photon Excitation and Second Harmonic Generation Microscopy

March 21, 2015

New: Our latest case study on qFibrosis' role in the successful development of Rezdiffra

Scientific Posters

Fibrosis regression after Tirzepatide treatment of Non- cirrhotic MASH for 52 weeks occurred in a zone-dependent manner

Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis

Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study

AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study

Evaluating impact of weight changes on histological patterns of liver fibrosis in MASH: implications for spatial interrogation

Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH

Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease

Evaluation of the consistency and heterogeneity of fibrosis assessment in adjacent virtual liver needle biopsies using AI- based qFibrosis

Independent validation of Second Harmonic Generation/Two- photon excitation imaging and artificial intelligence-based SNOF index for metabolic dysfunction associated steatohepatitis cirrhosis assessment

Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease

Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease

Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH

GWAS analysis and digital pathology at patients without MASLD improvements prospective cohort 1 year study

qBallooning AI-based ballooned hepatocyte detection and quantification by SHG TPE microscopy

Regional fibrosis progression analysed by digital pathology with artificial intelligence is associated with renal dysfunction

AI Digital pathology unmasked the “No Change” in conventional pathological assessment of MASLD patients with one year lifestyle intervention in a prospective cohort study

Validation of optimal liver biopsy size for reliable quantitation of fibrosis severity in different areas and structure of liver lobule using SHG with AI analyses

Assessment of fibrosis changes rates in placebo arm of MASH drug trials based on pathologist readouts and qFibrosis continuous values

Impact of sampling size on variability of fibrosis assessment in liver biopsies using SHG TPE and AI analysis based fibrosis staging

NITs as continuous measure of hepatic fibrosis in NAFLD

Validation of the HI AI DP platform as an aiding tool to increase pathologist concordance on fibrosis staging in NASH

Reducing screen failure rates for NASH clinical trials using ballooning and fibrosis assessment with SHG TPE microscopy and AI analysis – results from the TANDEM trial

Spatial distribution of collagen in MASLD affects levels of N terminal pro-peptide of type III collagen (PRO-C3)

The concomitant zonal quantification of qSteatosis and qFibrosis using HI AI DP improved detection of liver injury regression post-bariatric surgery

Differential anti-fibrotic effects of semaglutide and lanifranor demonstrated by AI DP in the biopsy-confirmed GAN BIO-MASH mouse model with advanced fibrosis and HCC

Assessment of resmetiron-mediated reductions of steatosis and concomitant ballooning utilizing quantitative SHG imaging

Use of multi-parametric measures to differentiate and better assess fibrosis patterns between baselie and EOT patients in NASH clinical trials – Results from the FALCON-1 and 2 clinical trials

Digital quantitation of fibrosis, septa parameters and treatment-induced changes in metabolic dysfunction-associated steatohepatitis F3 fibrosis

Comparing fibrosis distribution in lean versus overweight/obese NASH-cirrhosis patients using SHG/TPE microscopy: An observational analysis

Artificial Intelligence to Measure Fibrosis Change on Liver Biopsy in MAESTRO-NASH, a Phase 3 52-Week Serial Liver Biopsy Study in 966 Patients With NASH Treated With Resmetirom or Placebo

Impact of sampling size on variability of fibrosis assessment in liver needle biopsies using second harmonic generation/two photon excitation microscopy and artificial intelligence analysis based fibrosis staging

Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves nonalcoholic steatohepatitis (NASH) in a GAN diet induced and biopsyconfirmed mouse model

Validation and utility of artificial intelligence-based zonal annotations as an additional assessment tool for the histopathologic review of fibrosis in non alcoholic steatohepatitis patients

Artificial intelligence assisted qFibrosis as a pathological “biomarker” to evaluate disease severity in patients with hepatocellular carcinoma

Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH a phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo

A deep exploration of bridging fibrosis evolution and individual septa parameters in NASH using quantitative second harmonic generation imaging reveals fibrosis changes in natural history and treatment-induced not seen with conventional histology

Quantification of vessel and bile duct parameters using Second Harmonic Generation in patients with NAFLD across fibrosis stages

Digital pathology using stain-free imaging indices as a tool for fibrosis quantification in patients with congestive hepatopathy

Artificial Intelligence analysis of liver biopsies in pre-cirrhotic NASH: qFibrosis explained

Repeatability and reproducibility assessment and its acceptable standard error of means for qFibrosis system in multi site NASH clinical trials

Digital pathology with artificial intelligence analyses provides deeper insights into lifestyle intervention-induced fibrosis regression in NASH

Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models

Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty liver disease

Hepatic fat and liver volume reductions-impact on non-alcoholic steatohepatitis trials and potential solutions using concomitant fibrosis with ballooning with fibrosis

Advancement of artificial intelligence in digital pathology: from exploratory end point to primary end point in non-alcoholic steatohepatitis clinical trials

Understanding early stage fibrosis in NASH non-human primate model using AI digital pathology

Histological Correlation with Portal Pressures and Varices in NASH Cirrhosis using Quantitative Digital Pathology

Quantitative Assessment of Septa Formation and Progression in CDHFD Rat Model of NASH Using SHG/TPEF Microscopy

Quantitative Assessment of Septa Formation and Progression in CDHFD Rat Model of NASH Using SHG/TPEF Microscopy

Repeatability and reproducibility of qFibrosis for automated assessment of liver fibrosis

Use of Second-Harmonic Generation Microscopy for Automated Detection of Septa and Nodules in Needle Liver Biopsies of NASH Cirrhosis

Clinical relevance of an animal model of nonalcoholic steatohepatitis (NASH) and digital pathology with artificial intelligence (DP-AI) analyses of hepatic fibrosis

Derivation of Machine Learning Histologic Scores Correlating with Portal Pressures and the Development of Varices in NASH Patients with Cirrhosis

Impact of Artificial Intelligence Assistive Tool on the Histopathologic Review of Fibrosis in Non-Alcoholic Steatohepatitis Patients

Magnetic Resonance Elastography (MRE) Demonstrate the Strongest Correlation with Digital Pathology and NASH CRN Fibrosis Assessments, compared to Transient Elastography and Other Assessed Non-Invasive Tests (NITs)

Second Harmonic Generation Microscopy can Quantify and Subclassify Early Stages of NASH Fibrosis Progression: Data from a screen-failure cohort of a NASH phase 2 study

Characterisation of the novel Galectin-3 inhibitor GB1107 on CCl4-induced liver fibrosis in mice

Impact of Resmetirom-Mediated Reductions in Liver Volume and Steatosis Compared with Placebo on the Quantification of Fibrosis using Second Harmonic Generation in a Serial Liver Biopsy Study

Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment

Addressing the Heterogeneity of Fibrosis in Liver Biopsy Specimens with qFibrosis – a New Paradigm for an Old Problem

The Complexity of Ballooned Hepatocyte (BH) Identification: Time to Rethink Trial Endpoints for Nonalcoholic Steatohepatitis?

Development of Machine Learning Histological Scores that Correlated with Portal Pressures and Development of Varices in NASH patients with Cirrhosis

Unique fibrosis progression and regression features in NAFLD, validation of concept in animal and human studies using artificial intelligence analyses (DP-AI)

SHG/TPEF Microscopy Imaging in the Fibrosis and Steatosis Progression of Nonalcoholic Fatty Liver Disease (NAFLD) in Mouse Models

Second Harmonic Generation (SHG)/Two-Photon Excitation Fluorescence (TPEF) Microscopy Imaging and Quantitative Assessment of Septa Fibrosis in Choline Deficient High Fat Diet (CDHFD) Rat Model of Nonalcoholic Steatohepatitis (NASH)

qVessel, a Machine Learning-based Algorithm, Accurately Stages Liver Biopsies with Chronic Liver Disease, based on Automated Vessel Counting

AI Digital Pathology Using qFibrosis Reveals Heterogeneity of Fibrosis Regression in Hepatitis B and Hepatitis C Patients with SVR

Digital Pathology with Artificial Intelligence Analyses Reveal New Dynamics of Treatment Induced Fibrosis Regression in Nonalcoholic Steatohepatitis

Dynamic Fibrosis Features in HCV Post-treatment Liver Biopsies and Its Interpretation

Predict Early Recurrence of Hepatocellular Carcinoma Using Multi-dimensional Artificial Intelligence Analysis of Liver Fibrosis

The Significance Of Quantified Extracellular Matrix Features In Patients With Hepatocellular Carcinoma After Curative Liver Resection

Dynamic Fibrosis Features in Post-treatment Biopsies and its Interpretation

BMS-986263 (Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA) Safety and Target Engagement in Patients with Advanced Hepatic Fibrosis: Week 36 Results from a Phase 2 Randomized, Double-blind, Placebo-controlled Trial

Concomitant Zonal Quantification of qSteatosis and qFibrosis in a Sub-study from EMMINENCE, a 12-month Phase 2b NASH study of MSDC-0602K

Steatosis and Fibrosis Measured as Continuous Variables on Paired, Serial Liver Biopsies in the Resmetirom (MGL-3196) 36-week Phase 2 NASH Study

qFIBS for the Automated Quantitative Evaluation of Histological Evolution in Pediatric Nonalcoholic Steatohepatitis

Quantitative Imaging and Characterization of Collagen Patterns in High Grade Serous Ovarian Carcinoma (HGSOC)

Comparison of Various Quantitative and Qualitative Collagen Analysis Methods in Early Liver Fibrosis